ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.

Ophthalmology Glaucoma is a premier academic journal dedicated to advancing the understanding and management of glaucoma, a leading cause of irreversible blindness worldwide. Published by Elsevier, this journal covers a broad spectrum of topics within the field of ophthalmology, providing a platform for groundbreaking research and clinical insights. With an impressive impact factor that places it in the Q1 category of ophthalmology journals, and a commendable Scopus ranking of 29 out of 137, Ophthalmology Glaucoma is recognized for its rigorous peer-review process and high-quality publications. Since its inception in 2018, the journal has focused on disseminating innovative findings and treatment modalities to enhance patient care and outcomes. Researchers, clinicians, and students are encouraged to explore the Open Access options available, promoting wider accessibility to critical scientific knowledge. By staying at the forefront of ophthalmic research, Ophthalmology Glaucoma plays an essential role in shaping practices and policies that improve eye health globally.

ONCOLOGIST is a premier, open-access journal published by Oxford University Press, advancing the field of cancer research since its inception in 1996. With an impressive H-Index and a prestigious placement within the Q1 category in Cancer Research, Medicine, and Oncology for 2023, ONCOLOGIST stands at the forefront of oncological science, boasting a Scopus rank of #55 out of 404 in Medicine and #47 out of 230 in Cancer Research. This journal not only disseminates cutting-edge research but also aims to foster multidisciplinary approaches that are critical for addressing the complex challenges faced in cancer therapy and survivorship. Be part of a vibrant community as you explore impactful research articles that contribute to the global conversation on cancer. ONCOLOGIST is dedicated to providing an accessible platform for authors and readers alike, ensuring that high-quality research is available to all stakeholders in the fight against cancer.

Journal of Clinical Oncology is a premier academic journal published by Lippincott Williams & Wilkins, dedicated to the field of oncology and cancer research. Since its inception in 1983, this influential journal has consistently ranked in the Q1 category across multiple disciplines, including cancer research, medicine, and oncology, reflecting its critical role in shaping the future of cancer therapeutics and patient care. With a Scopus ranking of #9 in Medicine - Oncology and #6 in Biochemistry, Genetics and Molecular Biology - Cancer Research, Journal of Clinical Oncology publishes cutting-edge original research, reviews, and clinical updates that are essential for professionals, researchers, and students alike. Although it does not currently offer open access options, it provides invaluable insights and evidence-based findings that are crucial for advancing oncological knowledge and improving patient outcomes globally. The journal’s continued commitment to excellence ensures its place as a vital resource in the oncological community.

BMJ Supportive & Palliative Care is a leading academic journal dedicated to advancing the field of supportive and palliative care, published by the esteemed BMJ PUBLISHING GROUP in the United Kingdom. With an ISSN of 2045-435X and an E-ISSN of 2045-4368, this journal showcases high-quality, peer-reviewed articles that cater to a diverse audience, including healthcare professionals, researchers, and students. Notably, it holds a commendable impact factor, reflecting its credibility and influence within the academic community. As of 2023, the journal ranks in the top quartile (Q1) for Medical and Surgical Nursing and holds prestigious positions in the Q2 category for Medicine (miscellaneous) and Oncology (nursing), demonstrating its significance in multiple disciplines. Research published in this journal aims to enhance patient-centered care practices and improve health outcomes, making it an invaluable resource for innovative studies and discussions in the field. With a commitment to open access principles, BMJ Supportive & Palliative Care serves as a pivotal platform for disseminating knowledge and supporting the ongoing professional development of its readership.

Pediatric Hematology and Oncology, published by Taylor & Francis Inc, serves as a vital platform dedicated to the fields of hematology, oncology, and pediatrics, providing a comprehensive avenue for the dissemination of scholarly research and clinical advancements. With an ISSN of 0888-0018 and an E-ISSN of 1521-0669, this journal has successfully converged its expertise over the years from 1984 to 2024. Ranked in the Q3 category for Hematology and Oncology, alongside a Q2 ranking in Pediatrics, Perinatology, and Child Health (2023), it engages a diverse readership comprising researchers, healthcare professionals, and students eager to explore groundbreaking studies in child health and treatment methodologies. While it currently does not offer Open Access options, the journal is widely cited and recognized, particularly in its specialized fields, fostering a rich environment for dialogue and innovation in the management of pediatric hematological and oncological disorders. The journal is based in the United Kingdom at 530 Walnut Street, Ste 850, Philadelphia, PA 19106, making it an essential resource for those pursuing excellence in pediatric medical research.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, published by Lippincott Williams & Wilkins, is a pivotal journal in the fields of oncology and cancer research, focusing on the latest advancements in clinical trials and therapeutic strategies for cancer management. With an ISSN of 0277-3732 and an E-ISSN of 1537-453X, this journal serves as an essential resource for the dissemination of high-quality research findings, scholarly reviews, and innovative methodologies, aiming to advance clinical oncology from 1982 to 2024. It is categorized in Q3 for Cancer Research and Q2 for Oncology, reflecting its significant role in the scientific community. In addition to its rigorous peer-reviewed content, the journal provides a platform for researchers and clinicians to share valuable insights, laying the groundwork for future breakthroughs in cancer treatment. Although it currently does not offer open-access options, the journal remains accessible to a wide audience through academic institutions and libraries. The AMERICAN JOURNAL OF CLINICAL ONCOLOGY is crucial for anyone involved in oncology research, making it a must-read for professionals dedicated to improving cancer care.

BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.

Indian Journal of Neurosurgery, published by GEORG THIEME VERLAG KG, serves as a pivotal resource in the field of neurosurgery and clinical neurology. With an ISSN of 2277-954X and E-ISSN 2277-9167, this Open Access journal has made significant strides since its transition to an accessible format in 2012, ensuring that groundbreaking research is available to the global scientific community. The journal, situated in Stuttgart, Germany, aims to publish high-quality and innovative research, reviews, and discussions that address contemporary challenges in neurosurgery. Despite its recent ranking of 465/551 in Medicine (Surgery) and 361/400 in Medicine (Neurology - clinical), with percentiles of 15% and 9% respectively, the Indian Journal of Neurosurgery fosters a platform for emerging ideas that can propel advancements in neurosurgical practices. Researchers, professionals, and students are encouraged to contribute to and benefit from this dynamic publication, which continues to influence the evolution of neurosurgical knowledge and practices.

ACTA ONCOLOGICA is a prestigious multidisciplinary journal published by Medical Journal Sweden AB, dedicated to advancing cancer research and clinical practice. As a key resource in the field of oncology, the journal aims to publish high-quality articles that cover significant developments in cancer biology, treatment modalities, and innovative imaging techniques. With an ISSN of 0284-186X and an E-ISSN of 1651-226X, ACTA ONCOLOGICA operates in the United Kingdom and is recognized for its substantial impact, currently holding a Q2 ranking in the categories of Hematology, Medicine (miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging in 2023. The journal’s commitment to disseminating pivotal research is reflected in its inclusion in Scopus, with rankings placing it in the top half of its fields. Though it does not currently offer Open Access, it remains an essential resource for researchers, healthcare professionals, and students seeking to stay informed on the latest trends and findings in oncology. Established in 1963, the journal continues to be a cornerstone of cancer research well into 2024.